Stage protein expression difference spectrum model for systemic lupus erythematosus and construction method

Abstract

The invention relates to a stage protein expression difference spectrum model for systemic lupus erythematosus (SLE), and by comparing the differences between proteomics of an SLE patient in an active stage and a stationary stage and a normal person or a rheumatoid arthritis patient, the protein expression difference spectrum of the systemic lupus erythematosus is obtained, which is important to clinical diagnosis and disease investigation of the SLE. Moreover, the invention also relates to a construction method of the stage protein expression difference spectrum model for the systemic lupus erythematosus, and by adopting the isobaric tags for relative and absolute quantification (iTRAQ) multiple labeling tandem mass spectrum technology, protein of a human peripheral blood mononuclear cell can be effectively identified and quantified relatively; and by adopting the technology, the stage protein expression difference spectrum model of the human peripheral blood mononuclear cell of the SLE patient can be obtained, which helps to further clarify the pathogenesis of the SLE and provide new ways for diagnosing and treating the SLE.

Description

【Technical field】 [0001] The invention relates to the technical field of proteomics, in particular to a systemic lupus erythematosus staged protein expression difference map model and a construction method thereof. 【Background technique】 [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple systems of the body, with relapses and remissions occurring alternately. Men and women can develop the disease at any age, but the first onset occurs in young women under the age of 40. Mainly. The course of the disease is long, the outcome is unpredictable, and any organ can be damaged. Common clinical symptoms include fatigue, fever, arthritis, etc.; although the treatment, prognosis and long-term survival of SLE patients have been significantly improved in recent years, the morbidity and mortality of SLE are still high. Prolonged exposure will lead to obvious organ damage and functional limitation, and in severe cases, pathological damage to multi...

AI Technical Summary

Problems solved by technology

On the other hand, due to the complex clinical manifestations of SLE, the early and accurate diagnosis of SLE is still a major problem for clinicians.

Traditional laboratory diagnostic methods, including antinuclear antibody tests, cannot effectively meet clinical needs in terms of specificity or sensitivity, and no markers that can better reflect SLE disease activity have been found to monitor the disease process of SLE

Images